Olema Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. None. Item 6. Exhibits. ​ ​ ​ ​ ​ ​ ​ ​ Incorporated by Reference Exhibit Number Description Schedule Form File Number Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation . 8-K 001-39712 3.1 11/23/2020 3.2 Amended and Restated Bylaws. 8-K 001-39712 3.1 12/16/2022 10.1* ¥ Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated January 13, 2022 . ​ ​ ​ ​ 10.2* # Separation Agreement by and between the Registrant and Cyrus Harmon, dated March 21, 2023 . ​ ​ ​ ​ 10.3* # Separation Agreement by and between the Registrant and Kinney Horn, dated March 8, 2023 . ​ ​ ​ ​ 31.1* Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ ​ 32.1* † Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS* Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document ​ ​ ​ ​ 101.SCH* Inline XBRL Taxonomy Extension Schema Document ​ ​ ​ ​ 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ ​ 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ ​ 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ ​ 99 Table of Contents 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ ​ 104 Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ​ ​ ​ ​ ​ ​ * Filed herewith. # Indicates management contract or compensatory plan or arrangement. † The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. ¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material. ​ 100 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Olema Pharmaceuticals, Inc. Date: May 9, 2023 By: /s/ Sean Bohen, M.D., Ph.D. ​ ​ Sean Bohen, M.D., Ph.D. President and Chief Executive Officer ( Principal Executive Officer ) Date: May 9, 2023 By: /s/ Shane Kovacs ​ ​ Shane Kovacs Chief Operating and Financial Officer ( Principal Financial Officer and Principal Accounting Officer ) ​ ​ ​ 101